secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001723128-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B
--------------------------------------------------------------------------------

- Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.
- Full year 2025 net revenue $3.02B (+8% YoY); GAAP net income $72M; diluted EPS $0.22.
- Adjusted EBITDA FY25 $688M (+10% YoY); Q4 adj EBITDA $175M.
- FY25 adj diluted EPS $0.83 vs $0.58 prior year; Q4 adj EPS $0.21 vs $0.12.
- 2026 guidance: net revenue $3.05-$3.15B, adj EBITDA $720-$760M, adj EPS $0.93-$1.03.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/0001723128-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/amrx-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001723128-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer